Pharmaceutical

Super DC Vaccine by Shanghai Cell Therapy Group for Solid Tumor: Likelihood of Approval

Super DC Vaccine is under clinical development by Shanghai Cell Therapy Group and currently in Phase I for Solid Tumor.

Oct 3, 2023 - 20:00
Super DC Vaccine is under clinical development by Shanghai Cell Therapy Group and currently in Phase I for Solid Tumor.
Read the original article

Tags:

Previous Article

Nitric oxide by NOxy Health Products for Diabetic Foot Ulcers: Likelihood of App...

Next Article

MC-232 by MC2 Therapeutics for Hidradenitis Suppurativa: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

AbbVie reports 9.7% fall in global net revenues for Q1 2023

AbbVie reports 9.7% fall in global net revenues for Q1 ...

Apr 28, 2023

STAT+: Dana-Farber, in break with Brigham and Women’s, will build new cancer center with Beth Israel

STAT+: Dana-Farber, in break with Brigham and Women’s, ...

Sep 14, 2023

STAT+: Private equity-owned physician groups plan lobbying push on mergers

STAT+: Private equity-owned physician groups plan lobby...

Aug 1, 2023